Pfizer Inc’s experimental rheumatoid arthritis drug goes before an advisory panel next week, a potential blockbuster medicine that would revive faith in the company’s research if its benefits are deemed to outweigh its side effects. Most industry analysts expect the Food and Drug Administration’s expert committee to recommend approval despite risks posed by higher-than-normal cholesterol and liver enzyme levels and infections for patients taking tofacitinib during clinical trials.
